Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06212518
Other study ID # PEP-2306 3b
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date October 2, 2023
Est. completion date August 31, 2024

Study information

Verified date January 2024
Source PepsiCo Global R&D
Contact Matthew Hinkley, PhD
Phone 914-742-4975
Email Matt.Hinkley@pepsico.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary objective of this study is to analyze smart phone-based Transdermal Optical Imaging (TOI) features to develop a model that can discern hydration status, including: 1) at various timepoints throughout a 24-hour period in healthy adults from the general population (GENPOP), and 2) before and after a team coach-led training session in athletes competing in a sport (ATHLETE). TOI data will be collected alongside standard reference measures of hydration status. In this study each subject will serve as their own control.


Recruitment information / eligibility

Status Recruiting
Enrollment 1000
Est. completion date August 31, 2024
Est. primary completion date August 31, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 14 Years to 65 Years
Eligibility Inclusion Criteria: Both Study Arms (GENPOP and ATHLETE) - Subject is male or female - If female, subject is not pregnant - Subject is willing to avoid alcohol consumption 24 hours prior to visit(s) - Subject is willing to avoid wearing makeup to the study session or willing to remove it with facial wipes before the face scans - Subject is willing to shave facial hair if predetermined during the informed consent session it will interfere with TOI measurement - Able to speak, write, and read English - Provision of written consent to participate GENPOP Study - Study subject is 18-65 years of age, inclusive - Subject does not smoke (or has quit for at least 6 months) - Subject is not taking medication that may interfere with the study - Subject has no health conditions that would prevent completion of the trial as indicated on the general health questionnaire (GHQ) - Subject is willing to fast overnight (~8-12 hours) - Subject is willing to refrain from vigorous exercise for 48 hours - Subject is willing to eat the exact same food the day prior to each visit to the testing site ATHLETE Study - Study subject is 14-45 years of age, inclusive - Subject is participating in team sport training/competition - Subject is participating in a coach-led practice Exclusion Criteria: Both Study Arms (GENPOP and ATHLETE) - Subject has participated or currently enrolled in a clinical trial within the past 30 days - Subject has participated in any PepsiCo trial within past 6 months - Subject has a condition or is taking medication that the investigator believes would interfere with his/her ability to provide informed consent, comply with the study protocol, which might confound the interpretation of the study results, or put the person at undue risk - Subject is allergic to alcohol or facial cleansing wipes - Subject is employed by, or has a parent, guardian, or other immediate family member employed by a company that manufactures any products that compete with any Gatorade product. If subject is unsure if a company would be considered a competitor to Gatorade, they will be asked to please let the study investigator know the name of the other company and the nature of their relationship to that company before they sign the informed consent. GENPOP Study • Subject has a health condition or is taking medication that can be worsened by fluid restriction (participants who opt-in to fluid restriction study arm only)

Study Design


Related Conditions & MeSH terms


Intervention

Other:
GENPOP ad libitum fluid intake
Unrestricted fluid intake.
GENPOP fluid restriction
In the 24 hours between the first and last face scan, reduce fluid intake by approximately 75% (equating to approximately 700 ml (women) and 800 ml (men)).
ATHLETE ad libitum fluid intake
No restriction on fluid intake
ATHLETE restricted fluid intake
Not permitted to drink during training session.

Locations

Country Name City State
United States Pepsico R&D Life Sciences Bradenton Florida
United States PepsiCo R&D Gatorade Sports Science Institute Chicago Illinois
United States PepsiCo R&D, Gatorade Sports Science Institute Plano Texas
United States PepsiCo R&D, Gatorade Sports Science Institute Valhalla New York

Sponsors (1)

Lead Sponsor Collaborator
PepsiCo Global R&D

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Transdermal Optical Imaging (TOI) signals Blood flow patterns of the face obtained from the video camera on a smart phone Four time points for GENPOP over 24 hours (Day 1 ~8 a.m., ~11:30 a.m., ~3:30 p.m., Day 2 ~8.a.m.; for ATHLETES, on arrival before a single ~45 minute exercise training session and immediately following a 30 minute cool down period post-exercise
Primary Standard measurement of hydration status: Body mass change Body mass scale (Tanita, WB-800 Plus) to the nearest 0.01 kilogram (kg) Four time points for GENPOP over 24 hours (Day 1 ~8 a.m., ~11:30 a.m., ~3:30 p.m., Day 2 ~8.a.m.; for ATHLETES, upon arrival before a single ~45 minute exercise training session and again immediately after exercise
Primary Standard measurements of hydration status: Urine specific gravity Digital pen refractometer (Atago, PEN-Urine SG) Four time points for GENPOP over 24 hours (Day 1 ~8 a.m., ~11:30 a.m., ~3:30 p.m., Day 2 ~8.a.m.; for ATHLETES, upon arrival before a single ~45 minute exercise training session and again immediately after exercise
Primary Standard measurements of hydration status: Urine color Color range scale rated from dilute to concentrated. 1=clear through yellows and oranges with most orange =7 Four time points for GENPOP over 24 hours (Day 1 ~8 a.m., ~11:30 a.m., ~3:30 p.m., Day 2 ~8.a.m.; for ATHLETES, upon arrival before a single ~45 minute exercise training session and again immediately after exercise
Primary Standard measurements of hydration status: Thirst Categorical scale from 1=Not thirsty at all, to 7=very, very thirsty Four time points for GENPOP over 24 hours (Day 1 ~8 a.m., ~11:30 a.m., ~3:30 p.m., Day 2 ~8.a.m.; for ATHLETES, on arrival before a single ~45 minute exercise training session and immediately following a 30 minute cool down period post-exercise
Secondary Subject demographics - Age in years At screening
Secondary Subject demographics - Sex male or female At screening
Secondary Subject demographics - Ethnicity Hispanic or Latino, or not Hispanic or Latino At screening
Secondary Subject demographics - Race American Indian, Alaska native, Asian, Black or African American, Native Hawaiian or Pacific Islander, White At screening
Secondary Fitzpatrick classification of skin color Skin type from 1=White skin, always burns, never tans to 6 = Black skin, heavily pigmented, never burns, tans very easily At screening
Secondary Mood scale Rated from 1=Calm to 9=Irritated Four time points for GENPOP over 24 hours (Day 1 ~8 a.m., ~11:30 a.m., ~3:30 p.m., Day 2 ~8.a.m.; for ATHLETES, on arrival before a single ~45 minute exercise training session and immediately following a 30 minute cool down period post-exercise
Secondary Dietary and fluid intake Food and fluid intake recorded on a paper log For GENPOP from 24 hours prior to Day 1 visit (~8 a.m.) through end of testing period (Day 2 ~8 a.m.). For ATHLETES from 24 hours to prior to start of single ~45 minute exercise session (if fluid restricted) or to end of exercise (if ad lib fluid intake)
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04079543 - NPO and Patient Satisfaction in the Cath Lab N/A
Recruiting NCT06063655 - Effects of Two Novel Hydration Beverage Formulas on Rehydration in Adults N/A
Completed NCT05111392 - Hydration Dynamics and Influence of Beverage Composition Phase 1/Phase 2
Terminated NCT02486224 - Metabolomic Analysis of the Impacts of Hydration Status on Exercise Performance N/A
Recruiting NCT02249845 - Comparing the Diagnostic Accuracy of Clinical Dehydration Scales Among Small Children N/A
Completed NCT01285713 - IV Glucose for Dehydration Treatment Phase 2
Withdrawn NCT00691275 - Efficacy Study of IV Fluids Only vs Ondansetron to Treat Dehydration N/A
Completed NCT00360204 - Improving Health Outcomes for New Mothers and Babies Phase 3
Completed NCT00370968 - Zinc-ORS in Severe and Complicated Acute Diarrhea Phase 2/Phase 3
Completed NCT04076995 - INDIGO-2: The Effect of High Water Intake on Glucose Regulation in Low-drinkers N/A
Recruiting NCT05768789 - Buoy Electrolyte Study on Hydration Status of Active Men and Women N/A
Not yet recruiting NCT05428228 - Clinical Study to Evaluate the Effects of Two Novel Hydration Beverage Formulas on Rehydration in Healthy Adults N/A
Completed NCT04997031 - Tap Water Intake and Perceptions in US Latinx Adults
Completed NCT04536324 - The Absorption Rate of Subcutaneous Infused Fluid
Completed NCT02926989 - Intravenous Fluids in Hospitalised Children Phase 4
Completed NCT04874584 - Culturally Tailored Nurse Coaching Study for Cancer Symptom Management N/A
Completed NCT02265575 - Hylenex-Assisted Resuscitation in Kenya (HARK) Trial for the Management of Dehydration Phase 2
Completed NCT02206581 - Using Hydration Monitor to Detect Changes in the Hydration Status Athletes N/A
Completed NCT01893853 - Fluid Balance During Exercise in the Heat With Water, Flavored Placebo, or a Carbohydrate-electrolyte Beverage Intake (The APEX Study) N/A
Completed NCT01503996 - Drinking Habits of Glaucoma Patients and Age Matched Controls N/A